Blue Jet Healthcare’s stock witnessed a sharp rise of over 3% after Macquarie initiated coverage with an ‘Outperform’ rating and set a target price of ₹1,000. The brokerage firm is optimistic about the company’s strong position in the contrast media segment, a high-growth area in pharmaceuticals used for medical imaging.
Macquarie sees significant growth potential in Blue Jet Healthcare’s pharma Contract Development and Manufacturing Organization (CDMO) business. The company is expected to benefit from:
Expansion of Existing Molecules – Strengthening its core portfolio.
New Molecule Additions – Diversifying and expanding its product pipeline.
Strong Global Partnerships – Ensuring steady demand and market penetration.
Focus on Value-Added Products – Boosting profitability and revenue growth.
With these growth drivers in place, analysts expect strong top-line and bottom-line expansion in the coming years.
Blue Jet Healthcare’s stock opened at ₹754.90, reaching a high of ₹788.90 and a low of ₹754.90. The stock’s 52-week high stands at ₹844.80, while its 52-week low is ₹329.65. As of 9:56 AM, the shares were trading 2.89% higher at Rs 773.65.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash